Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06712628 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06712628 · ClinicalTrials.gov record · last posted 2026-07-30

A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

Study acronym: UP-RISING
StatusRecruiting
PhaseNot specified
SponsorAbbVie
Started2024-11-07
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or TNFi therapy. Around 678 participants will be enrolled in approximately 80 sites in Germany. Study recruitment will last approximately 24 months, and the study participation time will be up to 24 months, for a total study duration of approximately 48 months.

Protocol amendment history 1 change detected by DataLookout

2026-07-31
Trial sites expanded: 53 → 72 locations
Trial Details
NCT Number NCT06712628
Lead Sponsor AbbVie
Conditions Moderate to Severe Rheumatoid Arthritis
Enrollment 678 participants
Start Date 2024-11-07
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-30